MENLO TIMES

Artios Pharma Limited , a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in cancer, led by Michael T. Andriole, Christine Silverstein, Graeme Smith, Ian Smith, and others, has announced  the successful close of an oversubscribed $115 million Series D financing, co-led by founding investor SV Health Investors  and new investor RA Capital Management , with participation from new investor Janus Henderson Invest

Self.co , a Lithuania-based company, helping you uncover the true cause of your symptoms and guide you toward the right path to better health, led by Tautvydas Gylys, Gintautas Gylys, and Juozapas Zabukas, has secured  €2.56 million in funding, including €1.2 million led by  Iron Wolf Capital , joined by  Coinvest , NGL Ventures , and several angel investors, and a €1.36 million government grant from Innovation Agency Lithuania . Nearly 40% of people worldwide suffer from all

LambdaVision , developer of protein-based artificial retinas, led by Nicole L. Wagner, Jordan A. Greco, and Robert R. Birge, has secured  $7 million seed funding round co-led by Seven Seven Six  and Aurelia Foundry Fund , with additional support from Seraphim Space , providing runway into 2027. Millions worldwide lose their vision each year to retinal diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), with limited treatment options. The new

Cellcolabs , manufacturing High-Quality Mesenchymal Stromal Cells, led by Petter Hallman, Mattias Bernow, Lina Sörvik, Heidi Stensmyren, and others, has raised  $12 million in a round led by Titian Capital. Global demand for regenerative therapies is surging, yet high costs and limited production still restrict access for many patients. Stockholm-based Cellcolabs, founded in 2021 by Dr. Mattias Bernow, aims to change this through industrial-scale stem cell manufacturing. Its

Adaptam Therapeutics , a pioneering company in cancer immunotherapies specifically targeting the immunosuppressive myeloid tumor microenvironment, led by Asis Palazon, Pablo Cironi, Salvatore Cappadona, and José M. Mato, has secured  a €3 million (~$3.5 million) pre-seed financing round led by Criteria Bio Ventures . As part of the round, Criteria Bio Ventures’ Salvatore Cappadona, PhD, and Pablo Cironi, PhD, join Adaptam’s board of directors. The €3M funding will advance Ada

Continue Research , a 2-year-old research effort to identify and study upstream mechanisms in biology, started by Deepinder Goyal, has announced a $25 million fund to back researchers, funded by personal investment, and is not a part of Eternal. The next breakthroughs in aging biology are hiding in plain sight, emerging not from added complexity but from uncovering foundational mechanisms that control everything downstream. A $25M fund supports researchers testing ideas so si

NewLimit , a biotechnology company focused on human longevity, led by Blake Byers, Brian Armstrong, Cathy O'Hare, and Jacob Kimmel, has secured  an additional $45 million from Eli Lilly and Company, Duke Management Co., Section 32, and others, bringing its market capitalization to $1.62 billion. Insiders, including Kleiner Perkins, Dimension, Abstract, Human Capital, and Boost, also participated. Significant progress has been made in developing medicines that rejuvenate aging

Tubulis , reimagining antibody drug conjugates, led by Dr. Dominik Schumacher, Dr. Jonas Helma-Smets, Dr. Ingo Lehrke, Dr. Günter Fingerle-Rowson, MD, Dr. Björn Hock, Dr. Matthew Norkunas, and others, has secured  €308 million (USD 361 million) financing. The round was led by Venrock Healthcare Capital Partners  with participation from additional new investors Wellington Management  and Ascenta Capital . Existing investors who supported the Series C include Nextech Invest , E

Nabla Bio , making drug development designable with generative AI, led by Surge Biswas, Frances Anastassacos, Rose Harrison, and others, announced  a new, multi-year research collaboration with Takeda. Under the agreement, Nabla Bio will receive double-digit millions in upfront and research payments, with potential success-based payments exceeding $1 billion. The collaboration will deploy Nabla Bio’s Joint Atomic Model (JAM) platform across Takeda’s early-stage programs, incl

Phagos , the sustainable alternative to antibiotics, led by Alexandros Pantalis  and Adèle James , has secured 25 million euros Series A...

Trogenix Ltd  (“Trogenix”), a pioneering biotech company dedicated to developing innovative cancer therapies, led by Prof. Steve Pollard,...

Until Labs , the company developing reversible cryopreservation for patients in need of donor organs, led by Hunter Davis and Laura...

DaltonTx , a collaborative intelligence platform redefining how technology powers drug discovery, led by Dr. Garry Pairaudeau, Dr....

Conceivable Life Sciences , the World’s First AI-Powered Automated IVF Lab, led by Joshua Abram, Alan Murray, Alejandro Chavez-Badiola,...

Genoskin , bringing unparalleled expertise in skin biology and immunology to advance research and drug development efforts led by Pascal...

BoobyBiome , a startup spun out of University College London’s Great Ormond Street Institute of Child Health, led by Dr Lydia Mapstone,...

Integra Therapeutics , a global leader in cutting-edge gene writing tools to improve the efficacy, led by Avencia Sánchez-Mejíasa and...

NRG Therapeutics Ltd. (“NRG”) , an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, led...

MRM Health NV , a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and...

LIft BioSciences, a rapidly emerging biotech and the global leader in neutrophil immunotherapies, led by Alex Blyth(CEO and Founder),...